Vaccine Formulation Development Solution

We focus on the precise optimization of Lipid Nanoparticles (LNP), including the selection of cationic lipids, adjustment of N/P ratios, and the use of cryoprotectants. This ensures high encapsulation efficiency of RNA within the LNP and stable LNP particle size and PDI under ultra-low or even refrigerated conditions.

SuperStable™ is a proprietary stabilization technology that primarily increases the glass transition temperature (Tg') of the vaccine through optimized excipient combinations and formulation processes (such as lyophilization). The goal is to develop formulations that can be stored long-term at 2-8°C or even room temperature (e.g., 25°C), significantly reducing reliance on the traditional cold chain.

Adjuvant selection depends on the antigen type, desired immune response (e.g., Th1, Th2, CTL), and target species. We offer multi-stage screening: starting with prediction based on antigen characteristics and PRR ligand scanning, followed by in vitro cellular models to assess immune pathway activation, and finally, in vivo immunogenicity validation in animal models to ensure the optimal adjuvant match for your antigen.

Yes. Our nanoparticle and liposome delivery systems can be surface-functionalized (e.g., PEGylation, ligand conjugation) to achieve active or passive targeting of specific cell types (such as Dendritic Cells/APCs), thereby maximizing immunogenicity and delivery efficiency.

For small molecules or peptides, the key lies in covalent conjugation (Hapten Conjugate) and the delivery system. We typically recommend using potent adjuvants (such as oil emulsions, adjuvant emulsions) and controlled-release carriers (such as microspheres or nanoparticles) to enhance immunogenicity and prolong antigen exposure time, effectively breaking immune tolerance.